Yueqi Zhu

Jun 1, 2023 | frontiersin.org | Shandong Engineering |Slaven Pikija |Yueqi Zhu |Shinichiro Uchiyama

Introduction Antiplatelet therapy is recommended after non-cardiogenic ischemic stroke, aiming at limiting thrombosis on ulcer atherosclerotic plaque and subsequent distal embolism (1). Dual antiplatelet therapy (DAPT) with a P2Y12 receptor inhibitor is often recommended after neuroendovascular stenting, with a transition to aspirin monotherapy after follow-up endovascular angiography (2, 3).